drugset
drugset / Trial / NCT04809012

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

NCT04809012 ↗

Phase 2 Withdrawn Sorrento Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the efficacy of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected solid tumors.

Timeline

Start
2021-06
Primary completion
2024-06
Completion
2024-06

Outcome

Outcome not reported

Stopped: “Intended to be replaced with another Protocol”

Drugs

EvaluationDrugModalityDoseRoute
Subject STI-3031 Unknown 20 mg/kg Intravenous

Indications

refractory malignant neoplasm